Appearing as a promising advance in the battle against obesity, the drug is capturing considerable interest . This treatment combines the action of two recognized GLP-1 receptor agonists, liraglutide, plus an unique glucose-dependent incretin component. Early clinical results have demonstrated significant body loss in individuals with a high BM… Read More